Galderma raises 2026 sales outlook for Galderma stock

Published on 10/23/2026 at 10:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-nine-month sales reached USD 4.765 billion, up 25.1 percent year on year. Galderma stock costs EUR 202.50 on October 23, 2026 at CHF 43.4 billion value.

Sales outlook rises in 2026

Galderma reported USD 4.765 billion in first-nine-month sales on October 22, 2026.
The company lifted full-year growth guidance to 22.5-23.5 percent from 19-21 percent.
Galderma stock traded at EUR 202.50 at 10:00 a.m. CEST at Lang & Schwarz on October 23, 2026.
Market capitalization stood at CHF 43.4 billion on October 23, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma Group AG (ISIN CH1335392721) raised its 2026 sales-growth outlook after reporting USD 4.765 billion in net sales for the first nine months. The announcement dated October 22, 2026 gives Galderma stock a fresh operating benchmark, while the company keeps investing behind its dermatology portfolio.

Galderma said first-nine-month sales increased 25.1 percent at constant currency from the year-earlier period. Reported growth was 27.5 percent, with group sales rising from USD 3.737 billion in the first nine months of 2025 to USD 4.765 billion in the same 2026 period.

Guidance moves above the summer range

The company now expects 2026 net sales growth of 22.5-23.5 percent at constant currency, compared with its previous range of 19-21 percent. The new range is the second upgrade during 2026 and reflects stronger performance across Therapeutic Dermatology, Dermatological Skincare and Neuromodulators.

Third-quarter sales reached USD 1.632 billion, up 26.0 percent at constant currency from USD 1.289 billion in the year-earlier quarter. The company also maintained its Core EBITDA margin guidance at 26 percent at constant currency, signaling that growth investment remains part of the near-term plan.

What does the growth mean for margins?

The sales increase is broad enough to matter beyond one product category. Galderma identified volume growth and favorable mix as the main drivers for the first nine months, while Therapeutic Dermatology benefited from Nemluvio and its established portfolio. The company said its 2026 guidance excludes any contribution from the planned ZO Skin Health acquisition, which is expected to close in the fourth quarter of 2026 or early 2027.

The latest figures also put the operating update ahead of the first-half baseline. Galderma had reported USD 3.10 billion in first-half sales, up 24.6 percent, and a Core EBITDA margin of 25.6 percent in that period, according to the company's October 2026 investor materials carried on its newsroom page. The third-quarter update therefore combines faster sales growth with a broadly stable margin framework.

Stock price and company scale

For investors, the key test is whether the stronger outlook can support continued investment without weakening profitability. Galderma had a market capitalization of CHF 43.4 billion on October 23, 2026, and its primary listing is on SIX under the ticker GALD. The group operates in injectable aesthetics, dermatological skincare and therapeutic dermatology.

Galderma stock was trading at EUR 202.50 at Lang & Schwarz on October 23, 2026 at 10:00 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.